The Bayer-Monsanto merger reveals truths about Monsanto and its product cycle that have led CLSA to downgrading the stock to “underperform” from buy. In a September 15 report, analyst Mark Connelly says the details of the proposed deal point to structural weakness inside Monsanto and their product cycle that should be of concern to investors – concerns that are not properly priced into the market. Yesterday former US Department of Justice officials expressed concern over the merger.
Worries over merger are justified on several levels, report says
Worries raised by farmers that the two largest providers of crop fertilizers, pesticides, seeds and related products are justified. Saying those that suggest the proposed merger would...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full Article
